THIRD AMENDMENT TO THE MASTER
CLINICAL TRIAL AGREEMENT

This Third Amendment (“Third Amendment”) effective as of September 16, 2014 hereby amends the Master Clinical Trial Agreement dated March 16, 2009, Amendment #1 thereto dated May 31, 2012, and Amendment #2 thereto dated March 16, 2014, between The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Tyler and The University of Texas at Austin, (individually and collectively referred to as an “Institution”) and Hoffmann-La Roche Inc. and Roche Laboratories Inc. (each referred to as “Roche”) (the “Master Agreement (as amended)”)(each a “Party” and collectively the “Parties”).

WHEREAS, the Parties desire to amend the terms of the Master Agreement (as amended) as set forth below to extend the term of the Master Agreement for an additional two (2) months.

NOW, THEREFORE, in consideration of the mutual promises set forth herein and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties hereto promise and agree as follows:

1. Pursuant to Section 10 of the Master Agreement (as amended), the parties mutually agree to extend the term of the Master Agreement for an additional two (2) months until November 16, 2014.

THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK
IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to be duly executed as of the date written below.

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: Chris Green
Name: Chris G. Green, CPA
Title: Director, Office of Sponsored Programs
Date: 9-15-14

HOFFMANN-LA ROCHE INC.

By: Jerry Lamby
Name: Jerry Lamby
Title: Global Head, Operations Management
Date: Sep 17, 2014

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

By: __________________________
Name: _________________________
Title: __________________________
Date: _________________________

UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

By: __________________________
Name: _________________________
Title: __________________________
Date: _________________________

THE UNIVERSITY OF TEXAS AT AUSTIN

By: __________________________
Name: _________________________
Title: __________________________
Date: _________________________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER

By: __________________________
Name: _________________________
Title: __________________________
Date: _________________________

Amendment #3 to Roche Master Sponsor-Initiated Clinical Trial Agreement
Term: Expires November 16, 2014
IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to be duly executed as of the date written below.

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: __________________________
Name: _________________________
Title: __________________________
Date: __________________________

HOFFMANN-LA ROCHE INC.

By: ____________________________
Name: __________________________
Title: __________________________
Date: ________________

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

By: ____________________________
Name: Angela R. Charboneau Wishon, J.D.
Title: Vice President for Research Administration
Date: __________________________

UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS AT AUSTIN

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________
IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to be duly executed as of the date written below.

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: ________________________
Name: ________________________
Title: ________________________
Date: ________________________

HOFFMANN-LA ROCHE INC.

By: ________________________
Name: Jerry Wender
Title: Global Head, Operations Management
Date: Sep 17, 2014

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

By: ________________________
Name: ________________________
Title: ________________________
Date: ________________________

UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

By: ________________________
Name: ________________________
Title: ________________________
Date: ________________________

THE UNIVERSITY OF TEXAS AT AUSTIN

By: ________________________
Name: David Hawkins
Title: Associate Director, OSP
Date: 9.16.2014

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER

By: ________________________
Name: ________________________
Title: ________________________
Date: ________________________

Amendment #3 to Roche Master Sponsor-Initiated Clinical Trial Agreement
Term: Expires November 16, 2014
IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to be duly executed as of the date written below.

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

HOFFMANN-LA ROCHE INC.

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS SOUTH WESTERN MEDICAL CENTER

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS AT AUSTIN

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

Amendment #3 to Roche Master Sponsor-Initiated Clinical Trial Agreement
Term: Expires November 16, 2014
IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to be duly executed as of the date written below.

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

HOFFMANN-LA ROCHE INC.

By: __________________________
Name: Jerry Winkley
Title: Global Head, Operations Management
Date: Sep 17, 2014

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS AT AUSTIN

By: __________________________
Name: __________________________
Title: __________________________
Date: __________________________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER

By: __________________________
Name: David Anderson
Title: Director, Pre-Award Services
Date: September 16, 2014

Amendment #3 to Roche Master Sponsor-Initiated Clinical Trial Agreement
Term: Expires November 16, 2014

-2-
THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER AT HOUSTON

By: __________________

Digitally signed by
karen.niemeier@uth.tmc.edu
DN: 

Date: 2014.09.12 17:04:18

Annex 23

Amendment #3 to Roche Master Sponsor-Initiated Clinical Trial Agreement
Term: Expires November 16, 2014
## Second Amended Exhibit 1

### Administrative Contact Person and Address for Each Institution

<table>
<thead>
<tr>
<th>Institution</th>
<th>Contact Person</th>
<th>Phone</th>
<th>Fax</th>
<th>Tax ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The University of Texas at Austin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Hawkins</td>
<td>Associate Director</td>
<td>512-471-6424</td>
<td>512-471-6564</td>
<td>74-6000203</td>
</tr>
<tr>
<td><strong>The University of Texas Southwestern Medical Center</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angela R. Charboneau Wishon, J.D.</td>
<td>Vice President for Research Administration</td>
<td>214-648-6449</td>
<td>214-648-4474</td>
<td>75-6002868</td>
</tr>
<tr>
<td><strong>The University of Texas Health Science Center at San Antonio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chris Green</td>
<td>Director, Office of Sponsored Programs</td>
<td>210-567-2340</td>
<td>210-567-8107</td>
<td>74-1586031</td>
</tr>
<tr>
<td><strong>The University of Texas Health Science Center at Houston</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Niemeier</td>
<td>Director, Contracts</td>
<td>713-500-3999</td>
<td>713-383-3746</td>
<td>74-1761309</td>
</tr>
<tr>
<td><strong>The University of Texas Health Science Center at Tyler</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Anderson</td>
<td>Director, Office of Pre-Award Services</td>
<td>903-877-7486</td>
<td>903-877-7558</td>
<td>75-6001354</td>
</tr>
<tr>
<td><strong>The University of Texas Medical Branch at Galveston</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rohan Hebbar</td>
<td>Associate Legal Officer</td>
<td>409-747-8743</td>
<td>409-266-9470</td>
<td>74-6000949</td>
</tr>
</tbody>
</table>